Profile data is unavailable for this security.
About the company
N4 Pharma plc is a United Kingdom-based pre-clinical biotech company. The Company is engaged in developing Nuvec, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. The Company is building out its preclinical dataset and working towards first-in-human clinical data to support licensing deals for its Nuvec platform with gene therapy partners. Its lead program, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept program showcasing all the benefits of the Nuvec platform. ECP105 is a siRNA therapy intended for injection into the ocular cavity and contains a proprietary siRNA sequence to silence the fibrotic gene responsible for fibrosis (MRTF-B), or scarring, which occurs post-surgery. LipTide is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells.
- Revenue in GBP (TTM)7.07k
- Net income in GBP-1.07m
- Incorporated1979
- Employees4.00
- LocationN4 Pharma PLCWeston House, 1 Bradgate Park ViewDERBY DE73 5UJUnited KingdomGBR
- Phone+44 133 269 0061
- Fax+44 127 982 1300
- Websitehttps://www.n4pharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shortwave Life Sciences PLC | -4.30k | -353.20k | 868.17k | 2.00 | -- | 0.3526 | -- | -- | -0.0085 | -0.0085 | -0.0001 | 0.0454 | -0.0014 | -- | -- | -2,150.00 | -11.85 | -- | -12.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -19.39 | -- | 76.00 | -- | -- | -- |
| Roquefort Therapeutics PLC | 0.00 | -882.45k | 1.80m | 1.00 | -- | 0.3644 | -- | -- | -0.0063 | -0.0063 | 0.00 | 0.0302 | 0.00 | -- | -- | 0.00 | -15.04 | -- | -17.23 | -- | -- | -- | -- | -- | -- | -17.40 | 0.0747 | -- | -100.00 | -- | 44.29 | -- | -- | -- |
| ValiRx Plc | 49.78k | -1.78m | 2.34m | 14.00 | -- | 0.3417 | -- | 47.00 | -0.0094 | -0.0094 | 0.0002 | 0.0092 | 0.0147 | 0.00 | 0.6068 | 3,555.71 | -55.35 | -48.98 | -51.45 | -49.62 | 100.00 | -- | -3,775.95 | -16,086.59 | 8.87 | -- | 0.0022 | -- | 418.54 | -- | 5.99 | -- | -37.39 | -- |
| N4 Pharma PLC | 7.07k | -1.07m | 3.95m | 4.00 | -- | 2.24 | -- | 559.17 | -0.0025 | -0.0025 | 0.00002 | 0.0021 | 0.0045 | -- | 0.0756 | 1,767.50 | -71.04 | -59.59 | -74.91 | -63.90 | -- | -- | -15,981.33 | -67,987.22 | -- | -- | 0.00 | -- | 273.33 | -- | 16.60 | -- | -- | -- |
| TheraCryf PLC | 0.00 | -2.01m | 4.51m | 9.00 | -- | 0.9398 | -- | -- | -0.0017 | -0.0017 | 0.00 | 0.0022 | 0.00 | -- | -- | 0.00 | -41.20 | -38.70 | -53.79 | -42.97 | -- | -- | -- | -1,407.46 | -- | -- | 0.00 | -- | -100.00 | -- | 38.13 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m | 5.15m | 67.00 | -- | -- | -- | -- | -0.0028 | -0.0028 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -190.34 | -146.14 | -433.59 | -169.40 | -- | -- | -- | -- | 0.4766 | -2.42 | -- | -- | -- | -- | -26.15 | -- | -- | -- |
| OptiBiotix Health PLC | 1.15m | -191.00k | 6.04m | 5.00 | -- | 0.7177 | 431.65 | 5.25 | -0.0018 | -0.0018 | 0.0113 | 0.0815 | 0.134 | 1.93 | 2.88 | 230,200.00 | -2.22 | 17.23 | -2.33 | 17.84 | 45.44 | 50.78 | -16.59 | 189.34 | 3.75 | -- | 0.00 | 94.93 | 35.09 | 3.15 | 11.48 | -- | -- | -- |
| Futura Medical PLC | 7.93m | -6.29m | 7.53m | 12.00 | -- | 1.29 | -- | 0.9497 | -0.0207 | -0.0207 | 0.0261 | 0.01 | 1.06 | 137.36 | 8.58 | -- | -84.19 | -45.00 | -112.42 | -71.79 | 70.67 | -- | -79.41 | -108.25 | 2.21 | -- | 0.00 | -- | 349.09 | 237.55 | 119.85 | -- | 121.02 | -- |
| Talisman Metals PLC | 0.00 | 65.23k | 7.86m | 1.00 | -- | 3.28 | 120.55 | -- | -0.0064 | -0.016 | 0.00 | 0.0373 | 0.00 | -- | -- | 0.00 | 3.15 | -30.40 | 3.64 | -33.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 99.94 | -- | -- | -- |
| IXICO PLC | 6.53m | -1.65m | 8.22m | 79.00 | -- | 0.7007 | -- | 1.26 | -0.0186 | -0.0186 | 0.073 | 0.1267 | 0.5222 | -- | 3.18 | 82,708.86 | -13.19 | -3.47 | -15.43 | -4.03 | 48.71 | 55.52 | -25.27 | -6.21 | -- | -- | 0.015 | -- | 13.32 | -7.27 | 17.49 | -- | -5.30 | -- |
| Genflow Biosciences PLC | 0.00 | -1.80m | 8.88m | 5.00 | -- | -- | -- | -- | -0.005 | -0.005 | 0.00 | -0.0007 | 0.00 | -- | -- | 0.00 | -197.92 | -- | -648.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.68 | -- | -- | -- |
| Skinbiotherapeutics PLC | 4.64m | -696.25k | 15.55m | 41.00 | -- | 1.65 | -- | 3.35 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025 | 373.25k | 0.05% |
